S & C Biotech Co., Ltd. has been looking for a buyer or distributors to distribute our product, K-D, which is a medical device(clamp) for the ingrown toenail patients. We've been selling it to the DPM or Dermatologists, general surgeons. This surgical treatment with K-D is for a correction on deformity on ingrown toenails(pincer nails) specially came from the diabetes mellitus foot. The procedure is safe, simple, legal. If you're interested in, please let us know it.
we're willing to send the more details. Thank you in advance.
S & C Biotech Co., Ltd.
website :www.sncbiotech.co.kr
tel : 0082-2-470-1523 Fax : 0082-2-470-1533

Hanmi has shown outstanding growth since its establishment in 1973, and is now among the top pharmaceutical companies in Korea. Hanmi is a fully integrated company, producing from finished products to APIs in GMP certified facilities. Hanmi is also focusing on the development of new biopharmaceuticals and new chemical entities, and is pursuing further expansion in the global market.

Ⅰ. Finished Products: Currently focusing on the following 6 products developed by of Hanmi Pharmaceuticals for the global market:

1. Amosartan (Amlodipine Camsylate + Losartan K)
2. Esomeprazole Strontium
3. Simvastatin CR (Controlled Release)
4. Dexibuprofen ER (Extended Release) / Syrup
5. Clopidogrel Napadisilate

Ⅱ. APIs
Hanmi is a global leader of Cephalosporin APIs. Hanmi has been producing Cephalosporin APIs since 1987 and supplying more than 100 customers in about 50 countries worldwide, including European and US markets. Hanmi Cepha API site has been inspected and approved by US FDA, UK MHRA, and Hamburg BSG. We granted CEPs from EDQM for Cefotaxime sodium, Ceftriaxone sodium, Ceftazidime for Injection and Cefixime.

With success of Cepha business, Hanmi constructed cGMP-compliant API factory which is produced general APIs in 2007. This site has been inspected and approved by Hamburg BSG and TGA.

Ⅲ. Platform Technology
As the no.1 R&D investing pharmaceutical company in Korea, Hanmi’s long-term strategy is to concentrate on the development of biopharmaceuticals and new chemicals entities. More importantly, Long-Acting Protein/Peptide Discovery (LAPSCOVERY) Technology is Hanmi’s top priority platform technology. Currently, some of the major pipeline products started phase I clinical study in US as well as in Korea. Moreover, Hanmi has been developing new oncology pipeline including multiple tyrosine kinase inhibitor and oral anti-cancer drug. Based on its successful experiences and platform technologies, Hanmi is developing its own new products targeting the global market.

Expertise in pre-surgical planning for hip and knee replacement procedures. We offer a variety of product solution ranging from 3D medical modeling, Rapid Prototyping, custom implant design and instrumentation for orthopedics, pioneering in tissue sparing medical robotics applications.

koreamedicaltour

Dear ,

My name is Prince John Opoku from Ghana, i am contacting you in regards of my late father Gold Field, i lost my father four years ago and his workers cannot manage it properly and the business collapse, i am the first Son of the family and i am looking for a foreign Investor to assist me in this area. If you are interested contact me via email;princeopoku1999@voila.fr



Thanks
Prince John Opoku

ALPHAGENE is young and active corporation, actualizes innovative bio-science technology . We focus on studying market needs and wants to provide the best solution and satisfy the demend.

Product: Botulinum Toxin Type A

manufacture, R&D
Product
APIs, Finished product